These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30052728)

  • 1. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
    Kang SP; Gergich K; Lubiniecki GM; de Alwis DP; Chen C; Tice MAB; Rubin EH
    Ann Oncol; 2017 Jun; 28(6):1388-1398. PubMed ID: 30052728
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
    Tumeh PC; Hellmann MD; Hamid O; Tsai KK; Loo KL; Gubens MA; Rosenblum M; Harview CL; Taube JM; Handley N; Khurana N; Nosrati A; Krummel MF; Tucker A; Sosa EV; Sanchez PJ; Banayan N; Osorio JC; Nguyen-Kim DL; Chang J; Shintaku IP; Boasberg PD; Taylor EJ; Munster PN; Algazi AP; Chmielowski B; Dummer R; Grogan TR; Elashoff D; Hwang J; Goldinger SM; Garon EB; Pierce RH; Daud A
    Cancer Immunol Res; 2017 May; 5(5):417-424. PubMed ID: 28411193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
    Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
    Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
    Li F; Dong X
    Thorac Cancer; 2021 Dec; 12(23):3085-3087. PubMed ID: 34643064
    [No Abstract]   [Full Text] [Related]  

  • 7. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
    Peters S; Kerr KM; Stahel R
    Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
    Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
    Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced non-small cell lung cancer - Treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619
    [No Abstract]   [Full Text] [Related]  

  • 14. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
    Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
    Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
    [No Abstract]   [Full Text] [Related]  

  • 15. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
    Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
    Yamada H; Hida N; Satoh H; Yamagishi T; Hiroshima Y; Yoshii S; Saito T; Hizawa N
    Anticancer Drugs; 2019 Jan; 30(1):105-109. PubMed ID: 30074503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
    Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
    Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
    [No Abstract]   [Full Text] [Related]  

  • 19. Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
    Khalife N; Kordahi M; Felefly T; Saleh K
    Future Oncol; 2021 Jul; 17(20):2559-2562. PubMed ID: 34047193
    [No Abstract]   [Full Text] [Related]  

  • 20. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.